{
    "guideline_identifier": "PIIS0923753422018518.txt",
    "cancer_focus": {
        "primary_cancer": "Gastric adenocarcinoma",
        "related_syndrome_or_condition": [
            "Hereditary Diffuse Gastric Cancer (HDGC)",
            "Lynch syndrome",
            "Familial adenomatous polyposis (FAP)",
            "Li-Fraumeni",
            "Peutz-Jeghers",
            "Juvenile polyposis"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA (T1a)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Mucosal-confined tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Endoscopic resection (EMR/ESD) if well-differentiated, ≤2 cm, non-ulcerated",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Stage IB-III (Resectable)",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Operable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Perioperative chemotherapy + radical gastrectomy with D2 lymphadenectomy. Preferred: FLOT (5-FU/leucovorin/oxaliplatin/docetaxel; 4 pre-op + 4 post-op cycles). Alternative: Fluoropyrimidine + platinum for unfit patients",
                    "treatment_line": "Perioperative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA (FLOT), IIB (Alternative)"
                },
                {
                    "clinical_context": "After surgery without neoadjuvant",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Adjuvant fluoropyrimidine + oxaliplatin/docetaxel for 6 months",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [
                        {
                            "name": "MSI/MMR",
                            "status": "Non-MSI-H",
                            "testing_guidance": "Required for treatment decision"
                        }
                    ],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "MSI-H tumors after surgery",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Avoid adjuvant chemotherapy",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [
                        {
                            "name": "MSI/MMR",
                            "status": "MSI-H",
                            "testing_guidance": "Required for treatment decision"
                        }
                    ],
                    "esmo_evidence_level": "IV DI"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB-III",
            "risk_group": "Cytology-positive (CY+)",
            "treatment_plans": [
                {
                    "clinical_context": "Positive peritoneal washings",
                    "recommendation_type": "Management",
                    "recommendation_content": "Multidisciplinary tumor board discussion for curative surgery candidacy",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III B"
                }
            ]
        },
        {
            "staging_criteria": "Advanced/Metastatic Disease",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum (oxaliplatin preferred) + fluoropyrimidine (5-FU/capecitabine/S-1)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "First-line HER2-positive",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Trastuzumab + chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "HER2",
                            "status": "Positive",
                            "testing_guidance": "IHC 3+ or IHC 2+/FISH+"
                        }
                    ],
                    "esmo_evidence_level": "IA (ESCAT I-A)"
                },
                {
                    "clinical_context": "First-line PD-L1 CPS ≥5",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab + chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "CPS ≥5",
                            "testing_guidance": "Combined Positive Score (CPS)"
                        }
                    ],
                    "esmo_evidence_level": "IA (MCBS 4)"
                },
                {
                    "clinical_context": "First-line MSI-H/dMMR",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Consider pembrolizumab immunotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "MSI/MMR",
                            "status": "MSI-H/dMMR",
                            "testing_guidance": "Required for immunotherapy eligibility"
                        }
                    ],
                    "esmo_evidence_level": "IIA"
                },
                {
                    "clinical_context": "Second-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Ramucirumab + paclitaxel or ramucirumab monotherapy",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA (MCBS 2)"
                },
                {
                    "clinical_context": "Second-line antiangiogenic contraindicated",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Taxane or irinotecan",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA"
                },
                {
                    "clinical_context": "Third-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Trifluridine/tipiracil or taxane/irinotecan",
                    "treatment_line": "Third-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IA (MCBS 3)"
                }
            ]
        },
        {
            "staging_criteria": "Advanced/Metastatic Disease",
            "risk_group": "Low Peritoneal Carcinomatosis Index",
            "treatment_plans": [
                {
                    "clinical_context": "Peritoneal metastasis",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Consider cytoreduction + HIPEC",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Advanced/Metastatic Disease",
            "risk_group": "Oligometastasis",
            "treatment_plans": [
                {
                    "clinical_context": "Highly selected cases",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Consider metastasis resection",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "VC"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "HER2 positivity predicts trastuzumab efficacy",
            "PD-L1 CPS ≥5 predicts nivolumab response",
            "MSI-H/dMMR status indicates immunotherapy benefit and adjuvant chemotherapy avoidance",
            "Emerging biomarkers (FGFR2, claudin-18.2, EBV) under investigation for targeted therapies"
        ]
    }
}